IMBRELLA-A

NCT03148418 📎

Regimen

Experimental
atezolizumab monotherapy continuation (post-IMpower133)
Control
no control (extension of IMpower133 ITT)

Population

Extensive-stage small-cell lung cancer survivors from IMpower133 atezolizumab+carboplatin/etoposide arm enrolling in IMbrella A extension

Key finding

At 59.4-mo median follow-up, 3-/4-/5-year OS in atezolizumab+CE arm: 16% / 13% / 12%

Source: PMID 39306923

Timeline

    Guideline citations

    • CSCO SCLC 2025 (p.66)⚠️ OCR source